Our Life Sciences blog turns one year old! Click here for some fun facts about our first year of activity.
Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
In this paper we consider how a new generation of VR equipment promises to fundamentally change consumer experiences of virtual environments, including in the Life Sciences sector.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
23 May 2018 - Posted by: Daniel Lim
On 22 May 2018, FDA Commissioner Scott Gottleib gave an address at the Annual Board Meeting of the Alliance for Regenerative Medicine. The wide ranging speech focused on the promise of cell and gene therapies and the challenge that such new technologies present to the existing regulatory frameworks for development and approval. The key takeaways › Read More
22 May 2018 - Posted by: Juraj Gyarfas
On 17 May 2018, the European Commission announced that it had decided to close its infringement procedures and the treatment of complaints related to parallel trade of medicines for human use against Poland, Romania and Slovakia. By way of background, parallel trade has long been a major concern for both governments and pharmaceutical companies in › Read More
18 May 2018 - Posted by: Iradj Nazaryar
The Dutch Data Protection Authority (DPA) recently published information on its website with respect to the application of the right to be forgotten and data portability to medical records under the General Data Protection Regulation ((EU) 2016/679) (GDPR). According to the DPA, the right to data portability applies only to the personal data that the › Read More
16 May 2018 - Posted by: Eveline Van Keymeulen
The Federal Agency for Medicines and Health Products recently launched a new medicinal product database containing information on all medicinal products for human and veterinary use authorised in Belgium. This includes medicinal products that have a valid marketing authorisation, registration, authorisation for parallel import or temporary authorisation for use in Belgium. The database includes a › Read More
14 May 2018 - Posted by: Eveline Van Keymeulen
On 18 April 2018, two orders further detailing the rules on non-interventional and low-interventional trials in France entered into force. The first order replaces a May 2017 Order that established a list of interventions allowed in low-interventional trials (see our previous blog post, France further clarifies scope of clinical trial rules). Low-interventional trials are trials › Read More